Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness

Simply Wall St.05-03

AdvertisementWhat recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2632047726?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-05-03 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632047726","market":"hk","top_or_hot":-1,"title":"Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-03 17:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1","article_id":"2632047726","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adpt/adaptive-biotechnologies/news/assessing-adaptive-biotechnologies-adpt-valuation-after-rece-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2632047726","pubTimestamp":1777800375,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What recent performance says about Adaptive Biotechnologies\nAdaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past week, a small decline over the past month, and a sharper pullback over the past 3 months.\nSee our latest analysis for Adaptive Biotechnologies.\nAt a share price of $14.27, Adaptive Biotechnologies has had a weak stretch in recent months, with a 30 day share price return of a 3.65% decline and a 90 day share...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"在近期股价疲软后评估适应性生物技术(ADPT)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1.5},"content_text":"AdvertisementWhat recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in the stock, with a slight gain over the past week, a small decline over the past month, and a sharper pullback over the past 3 months. See our latest analysis for Adaptive Biotechnologies. At a share price of $14.27, Adaptive Biotechnologies has had a weak stretch in recent months, with a 30 day share price return of a 3.65% decline and a 90 day share price return of a 22.4% decline, while longer term total shareholder returns of 45.02% over 1 year and 124.72% over 3 years point to investors reassessing both growth potential and risk over time. If you are interested in how other healthcare names tied to artificial intelligence are trading right now, it is worth scanning the 33 healthcare AI stocks With ADPT trading at $14.27, a value score of 4, an intrinsic discount estimate of 36.76% and analyst targets implying further upside, the key question is whether this is a genuine entry point or if the market already reflects future growth. Most Popular Narrative: 30.6% Undervalued Against the last close of $14.27, the most followed narrative points to a fair value around $20.57, framing Adaptive Biotechnologies as materially undervalued based on long term fundamentals and cash flow potential.  Marked improvement in profitability, with the MRD segment now EBITDA positive and company wide cash burn improving 36% year over year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.  Read the complete narrative. Curious what sits behind that valuation gap? The narrative leans heavily on sustained revenue expansion, a future step up in margins, and a premium earnings multiple that assumes meaningful progress on scaling the business and monetising its immune medicine platform. Result: Fair Value of $20.57 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on MRD and immune medicine scaling as planned. Any stumble in key partnerships or sustained company wide losses could quickly challenge that 30.6% undervalued thesis. Find out about the key risks to this Adaptive Biotechnologies narrative. Next Steps With sentiment clearly mixed, it helps to see the full picture for yourself and move quickly while the facts are fresh in mind, starting with the 4 key rewards and 2 important warning signs. Looking for more investment ideas? If you stop with just one stock, you could miss better fits for your goals. Consider spending a few minutes scanning targeted stock ideas built from clear fundamentals.  Spot potential value candidates early by reviewing a focused set of screener containing 25 high quality undiscovered gems before they appear on more crowded radars. Prioritise resilience by checking a curated group of 69 resilient stocks with low risk scores that score well on stability and risk metrics. Strengthen your core holdings by scanning companies in the solid balance sheet and fundamentals stocks screener (44 results) that pair financial robustness with fundamental support.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2632047726","isCrawlerRequest":true}